Hemosol

HML-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about HML-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
January 23, 2002
Have ahd difficulties in their trials. May have a weak cash position.
Hemosol (HML-T)
January 23, 2002
Have ahd difficulties in their trials. May have a weak cash position.
Mike Weir
Managing Director, Guardian Capital
Price
$7.450
Owned
Unknown
DON'T BUY
DON'T BUY
January 9, 2002
Starting to move up, but prefers to wait for the product to start selling.
Hemosol (HML-T)
January 9, 2002
Starting to move up, but prefers to wait for the product to start selling.
David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$9.000
Owned
Unknown
BUY
BUY
December 31, 2001
A long term situation, but expects it will do OK.
Hemosol (HML-T)
December 31, 2001
A long term situation, but expects it will do OK.
Malvin Spooner
Chairman and Chief Executive Officer, Mavrix Fund Management
Price
$7.350
Owned
Unknown
BUY
BUY
December 28, 2001
Sees it going up. Use a $6.90 stop loss. Expects it to get to $8.75 at which time it should be looked at again.
Hemosol (HML-T)
December 28, 2001
Sees it going up. Use a $6.90 stop loss. Expects it to get to $8.75 at which time it should be looked at again.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$7.490
Owned
Unknown
WAIT
WAIT
December 21, 2001
A lot of competition in blood substitutes.
Hemosol (HML-T)
December 21, 2001
A lot of competition in blood substitutes.
Robert Floyd
President, R A Floyd Management
Price
$7.400
Owned
Unknown
DON'T BUY
DON'T BUY
December 6, 2001
Prefers other companies that have earnings. Might buy at $3.
Hemosol (HML-T)
December 6, 2001
Prefers other companies that have earnings. Might buy at $3.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$5.900
Owned
Unknown
DON'T BUY
DON'T BUY
November 28, 2001
Wait for FDA approval.
Hemosol (HML-T)
November 28, 2001
Wait for FDA approval.
Joe Connolly
Director of Resource and Trading, Cockfield Porretti Cunningham
Price
$6.020
Owned
Unknown
DON'T BUY
DON'T BUY
November 27, 2001
If you own, hold.
Hemosol (HML-T)
November 27, 2001
If you own, hold.
John Zechner
Chairman, J. Zechner & Assoc
Price
$6.250
Owned
Unknown
DON'T BUY
DON'T BUY
November 26, 2001
Watch how the trials go.
Hemosol (HML-T)
November 26, 2001
Watch how the trials go.
Fred Ketchen
Managing Director, Scotia McLeod
Price
$6.400
Owned
Unknown
WEAK BUY
WEAK BUY
November 22, 2001
Analysts are expecting a large upside. Will take time to get through the FDA phases.
Hemosol (HML-T)
November 22, 2001
Analysts are expecting a large upside. Will take time to get through the FDA phases.
Robert Floyd
President, R A Floyd Management
Price
$6.500
Owned
Unknown
DON'T BUY
DON'T BUY
November 5, 2001
Wait for FDA approval to go through. Will be a good product.
Hemosol (HML-T)
November 5, 2001
Wait for FDA approval to go through. Will be a good product.
David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$4.800
Owned
Unknown
BUY
BUY
October 25, 2001
A worthwhile stock to own a little bit. At a good price.
Hemosol (HML-T)
October 25, 2001
A worthwhile stock to own a little bit. At a good price.
Brendan Caldwell
President, Caldwell Securities
Price
$6.450
Owned
Unknown
WEAK BUY
WEAK BUY
October 11, 2001
Good product. Phase 3is delayed for a year. Lots of competition, but room for all. Speculative.
Hemosol (HML-T)
October 11, 2001
Good product. Phase 3is delayed for a year. Lots of competition, but room for all. Speculative.
Richard Stone
President, Stone Funds
Price
$5.980
Owned
Unknown
DON'T BUY
DON'T BUY
September 7, 2001
Will take a while for the product to come on stream. Has strong competition.
Hemosol (HML-T)
September 7, 2001
Will take a while for the product to come on stream. Has strong competition.
Fred Ketchen
Managing Director, Scotia McLeod
Price
$4.470
Owned
Unknown
DON'T BUY
DON'T BUY
September 5, 2001
High valuation and delay on trials was a downer.
Hemosol (HML-T)
September 5, 2001
High valuation and delay on trials was a downer.
Ian Nakamoto
Director of Research, MacDougall, MacDougall & MacTier
Price
$4.700
Owned
Unknown
Showing 31 to 45 of 78 entries